Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Lehtinen, Julia ^a   Raki, Mari ^a   Bergström, Kim A ^a   Uutela, Päivi ^a   Lehtinen, Katariina ^a   Hiltunen, Annukka ^a   Pikkarainen, Jere ^b,c   Liang, Huamin ^a   Pitkänen, Sari ^c   Määttä, Ann Marie ^b   Ketola, Raimo A ^a   Yliperttula, Marjo ^a   Wirth, Thomas ^c   Urtti, Arto ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Finland Ark Therapeutics Oy   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CETUXIMAB; DOXORUBICIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER LOCALIZATION; CELL ASSAY; CONTROLLED STUDY; DRUG COATING; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OVARY CARCINOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; AVIDIN; BIOTIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPOSOMES; MICE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

MUS;

EID: 84864383701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041410     Document Type: Article

References (43)

1. Perez-Soler R, (2004) HER1/EGFR targeting: Refining the strategy. Oncologist 9: 58-67.
2. Wells A, (1999) EGF receptor. Int J Biochem Cell Biol 31: 637-643.
3. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, et al. (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992.
4. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, et al. (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55: 3752-3756.
5. Maruyama K, (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63: 161-169.
6. Mastrobattista E, Koning GA, Storm G, (1999) Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 40: 103-127.
7. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, et al. (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 97: 1802-1807.
8. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, et al. (2003) A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 63: 354-363.
9. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, et al. (2004) Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-hodgkin lymphoma. Blood 104: 227-236.
10. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH, (2003) Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 44: 400-411.
11. Weber PC, Ohlendorf DH, Wendoloski JJ, Salemme FR, (1989) Structural origins of high-affinity biotin binding to streptavidin. Science 243: 85-88.
12. Lesch HP, Kaikkonen MU, Pikkarainen JT, Ylä-Herttuala S, (2010) Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv 7: 551-564.
13. Nobs L, Buchegger F, Gurny R, Allemann E, (2006) Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 17: 139-145.
14. Pulkkinen M, Pikkarainen J, Wirth T, Tarvainen T, Haapa-aho V, et al. (2008) Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur J Pharm Biopharm 70: 66-74.
15. Xiao Z, McQuarrie SA, Suresh MR, Mercer JR, Gupta S, et al. (2002) A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol 94: 171-184.
16. Pan H, Han L, Chen W, Yao M, Lu W, (2008) Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release 125: 228-235.
17. Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, et al. (2007) Biodistribution, pharmacokinetics and imaging of (188)re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 34: 415-423.
18. Lin YY, Li JJ, Chang CH, Lu YC, Hwang JJ, et al. (2009) Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. Cancer Biother Radiopharm 24: 453-460.
19. Zavaleta CL, Phillips WT, Soundararajan A, Goins BA, (2007) Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int J Pharm 337: 316-328.
20. Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, et al. (2008) Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 109: 411-417.
21. Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, et al. (2011) An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 11: 294.
22. Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S, (1997) Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1327: 181-192.
23. Ishida T, Okada Y, Kobayashi T, Kiwada H, (2006) Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm 309: 94-100.
24. Lehtinen J, Hyvönen Z, Subrizi A, Bunjes H, Urtti A, (2008) Glycosaminoglycan-resistant and pH-sensitive lipid-coated DNA complexes produced by detergent removal method. J Control Release 131: 145-149.
25. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, et al. (2007) Gold nanoparticles enable selective light-induced contents release from liposomes. J Control Release 122: 86-93.
26. Kullberg M, Mann K, Owens JL, (2009) A two-component drug delivery system using her-2-targeting thermosensitive liposomes. J Drug Target 17: 98-107.
27. Kirchmeier MJ, Ishida T, Chevrette J, Allen TM, (2001) Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Liposome Res 11: 15-29.
28. Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang L, et al. (2008) Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 109: 411-417.
29. Gabizon A, Horowitz AT, Goren D, Tzemach D, Mandelbaum-Shavit F, et al. (1999) Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies. Bioconjug Chem 10: 289-298.
30. Lehtinen J, Magarkar A, Stepniewski M, Hakola S, Bergman M, et al. (2012) Analysis of cause of failure of new targeting peptide in PEGylated liposome: Molecular modeling as rational design tool for nanomedicine. Eur J Pharm Sci 46: 121-130.
31. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC, (1993) Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898.
32. Lee CM, Tannock IF, (2010) The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 10: 255.
33. Huhtala T, Laakkonen P, Sallinen H, Ylä-Herttuala S, Närvänen A, (2010) In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies. Nucl Med Biol 37: 957-964.
34. Sadzuka Y, Nakai S, Miyagishima A, Nozawa Y, Hirota S, (1997) Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin. Cancer Lett 111: 77-86.
35. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, et al. (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65: 11631-11638.
36. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, et al. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 6732-6740.
37. Chuang KH, Wang HE, Chen FM, Tzou SC, Cheng CM, et al. (2010) Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. Mol Cancer Ther 9: 1903-1912.
38. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, et al. (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28: 157-159.
39. Bolotin EM, Cohen R, Bar LK, Emanuel N, Ninio S, et al. (1994) Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 4: 455-479.
40. de Jong J, Bast A, van der Vijgh WJF, (1993) Analysis of anthracycline antitumor drugs in tissues and body fluids using liquid chromatography. Trends in Anal Chem 12: 422-428.
41. Hsieh YJ, Chang CH, Huang SP, Lin CW, Wang MN, et al. (2008) Effect of cyclosporin A on the brain regional distribution of doxorubicin in rats. Int J Pharm 350: 265-271.
42. Goins BA, Phillips WT, (2003) Radiolabelled liposomes for imaging and biodistribution studies. In Torchilin VP & Weissig V, editors. Liposomes. Oxford University Press, USA, 319-336.
43. Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, et al. (2005) Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. Bioconjug Chem 16: 131-138.